The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure
NCT ID: NCT05797220
Last Updated: 2024-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
217 participants
OBSERVATIONAL
2016-11-04
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Botulinum Toxin and Sphincterotomy in the Treatment of Chronic Anal Fissure
NCT01095900
Complex Treatment of a Chronic Anal Fissure
NCT03855046
Botulinum Toxin Type A in the Treatment of Chronic Anal Fissure
NCT05598164
Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure
NCT05590520
High Dose Multiple Site Injection of Botox Versus Lateral Sphincterotomy in Chronic Analfissure
NCT04166175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Botulinum toxin group
The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters.
Botulinum Toxin Type A Injection [Botox]
Botulinum toxin plus topical diltiazem group
The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters. After BT injection, topical 2% diltiazem gel was prescribed, applied 2 times per day for 10 days (2 doses of 1 gr each per day). No selection criteria were used when recommending this treatment; it was randomly suggested to some for a while during the cohort since the surgeon believed it might enhance the efficacy of BT.
Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum Toxin Type A Injection [Botox]
Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who completed at least 24 months of follow-up (3rd day, 10th day, 1st-month, and 2nd-month face-to-face clinic visits and 6, 12, and 24 months phone calls)
* Patients who received conservative treatments including topical diltiazem and nitrites
Exclusion Criteria
* Patients with inflammatory bowel diseases
* Patients with accompanying anorectal disease (hemorrhoids, anal fistula, abscess)
* Patients who underwent botulinum toxin injection within 1 year before recruitment
* Patients with anterior, lateral, or multiple fissures
* Comorbidities (AIDS, sexually transmitted disease, tuberculosis, leukemia)
* Pregnancy
* Prescription of calcium canal blockers or nitrites
* Hypersensitivity to diltiazem or botulinum toxin
* Patients without anal pain
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Medipol University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cigdem Arslan
Consultant Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naciye Cigdem Arslan, MD
Role: PRINCIPAL_INVESTIGATOR
Medipol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Medipol University
Istanbul, Other (Non U.s.), Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-10840098-772.02-786
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.